Dr. Petrylak on Atezolizumab in Bladder Cancer

Daniel P. Petrylak, MD
Published: Tuesday, Dec 15, 2015



Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

In the phase I trial, it was demonstrated that patients that had high levels of PD-L1 staining in the immune cells, either 2+ or 3+, had a better survival than those patients who had 0-1+ PD-L1 levels, says Petrylak.

However, even those patients who had had 0-1+ PD-L1 levels, still benefited, with a median survival of eight months. The 2+/3+ patient group has not yet reached median survival, he adds.

This is an active drug in bladder cancer, says Petrylak.


Daniel P. Petrylak, MD, professor of medicine at Yale University Cancer Center, discusses the anti–PD-L1 antibody atezolizumab in bladder cancer.

In the phase I trial, it was demonstrated that patients that had high levels of PD-L1 staining in the immune cells, either 2+ or 3+, had a better survival than those patients who had 0-1+ PD-L1 levels, says Petrylak.

However, even those patients who had had 0-1+ PD-L1 levels, still benefited, with a median survival of eight months. The 2+/3+ patient group has not yet reached median survival, he adds.

This is an active drug in bladder cancer, says Petrylak.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x